Klingon Empire Pharmaceuticals is expecting a growth rate of 14% for the next two years due to its new flu preventive drug, Katterracsin. Thereafter it should level to an 8% growth rate. The last dividend paid was $.65 per share. What price should the stock sell for if investors require 12% return